Streetbeat News

Regulatory

DDD

3D Systems has received a notice from the NYSE for not filing its Form 10-K on time. The company has until September 15, 2024, to file the Form 10-K with the SEC to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 12:04 pm

AAPL

FDX

LULU

NKE

QQQ

RDDT

SPY

TSLA

U.S. stocks are poised for a strong finish to the week, buoyed by rate-cut optimism and anticipation of Fed Chair Powell's speech. The S&P 500's rally this year is deemed 'perfectly normal' by analysts, following a downturn in the midterm year. Futures are up in premarket trading, with notable movements in individual stocks like FedEx, Lululemon, NIKE, and Tesla following earnings announcements and production news. Global markets show mixed reactions, with commodities and bonds also displaying varied trends.

Portfolio Pulse from Shanthi Rexaline

March 22, 2024 | 11:38 am

NVS

VGK

On 21 March 2024, the CHMP recommended granting marketing authorization for Novartis' Fabhalta1, aimed at treating Paroxysmal Nocturnal Haemoglobinuria.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:15 am

NVO

VGK

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Novo Nordisk's Awiqli, intended for the treatment of diabetes mellitus. This recommendation is a crucial step towards the commercial availability of Awiqli in the European market.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:13 am

AAPL

Apple Inc. (NASDAQ:AAPL) has filed a patent for an all-glass MacBook Pro, potentially featuring a touchscreen. The patent suggests the use of glass for the MacBook Pro's back and possibly for the front and back surfaces of the display, with a metal housing for the sides. This development is part of Apple's exploration into innovative display technologies, including touchscreens for MacBook computers and foldable screens for iPads or MacBooks.

Portfolio Pulse from Ananya Gairola

March 22, 2024 | 11:10 am

PFE

Pfizer Inc. (NYSE:PFE) received a positive opinion from the CHMP of the EMA for its novel antibiotic combination, EMBLAVEO®. This recommendation is for the treatment of adult patients with multidrug-resistant infections, including cIAI, HAP, VAP, and cUTI, with limited treatment options. The MAA for EMBLAVEO® underwent an accelerated assessment due to its significance for public health and therapeutic innovation.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:09 am

TECH

Bio-Techne has been granted European IVDR certification for its diagnostic test designed to monitor Chronic Myeloid Leukemia. This certification allows the company to market and sell the test in European markets, potentially expanding its customer base and increasing revenue from its diagnostic products segment.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:07 am

AEVA

Aeva Technologies announced it has regained compliance with NYSE continued listing standards, indicating a positive development for the company's stock market presence.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:05 am

OTLK

VGK

On 21 March 2024, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Outlook Therapeutics' Lytenava for the treatment of neovascular age-related macular degeneration. This positive opinion is a crucial step towards the marketing authorization of Lytenava in the European Union.

Portfolio Pulse from Charles Gross

March 22, 2024 | 10:54 am

MTNB

Matinas BioPharma has regained compliance with the NYSE American's continued listing standards, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 10:31 am